Literature DB >> 23897417

Mortality of necrotizing enterocolitis and isolated ileal perforation at a single institution over the past 40 years.

E Marty Knott1, Alessandra Gasior1, Shawn St Peter1, Charles Snyder1.   

Abstract

PURPOSE: Controversy exists regarding differences in mortality between isolated ileal perforation (IIP) and necrotizing enterocolitis (NEC). We sought to identify risk factors and determine mortality rates for these two entities.
METHODS: A retrospective review was conducted on all patients with NEC or IIP undergoing surgical management at our institution from May 1971 to December 2011. Demographics, birth history, management strategies, and mortality were recorded. Chi-square and unpaired t-test were used where appropriate.
RESULTS: During the study period, 236 patients underwent operative management with 17.8% of those being for IIP. Patients with IIP had a lower estimated gestational age (27.8 ± 3.0 vs. 29.5 ± 4.2 weeks, p = 0.014), were more likely to be of multiple gestation (33.3 vs. 16.5%, p = 0.022), and were younger at diagnosis (8.7 ± 8.1 vs. 14.3 ± 11.1 days, p = 0.003) compared with those undergoing operation for NEC. Mortality was threefold lower with IIP (9.5 vs. 36.1%, p < 0.001).
CONCLUSIONS: IIP carries a unique set of risk factors and has a significantly lower mortality rate when compared with NEC. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23897417     DOI: 10.1055/s-0033-1351665

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  2 in total

1.  Differences in mortality characteristics in neonates with Down's syndrome.

Authors:  C L Cua; U Haque; S Santoro; L Nicholson; C H Backes
Journal:  J Perinatol       Date:  2017-01-12       Impact factor: 2.521

2.  Primary laparotomy is effective and safe in the treatment of necrotizing enterocolitis.

Authors:  Stefan Gfroerer; Henning Fiegel; Rolf L Schloesser; Udo Rolle
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.